METHOD OF CONSTRUCTING ALLOGENIC AND DRUG RESISTANT T-CELLS FOR IMMUNOTHERAPY Russian patent published in 2019 - IPC C12N5/783 A61K35/17 A61K45/06 A61P35/00 

FIELD: biotechnology.

SUBSTANCE: present invention relates to biotechnology, specifically to cell technologies, and can be used in medicine for cancer immunotherapy. Ex-vivo method for producing clofarabine and / or fludarabine-resistant T-cells involves the steps of: (a) transfecting T cells with a nucleotide sequence encoding a low-boiling endonuclease, specifically directed to a gene expressing an enzyme having deoxycytidine kinase activity (dcK – EC 2.7.1.74); (b) expressing said endonuclease in said T-cells to achieve targeted inactivation of said dcK gene; (c) propagation of said engineered T-cells obtained in step (b), optionally in the presence of clofarabine and / or fludarabine. Said T-cells represent allogenic T-cells from the donor, in which the gene coding the T-cell receptor component (RTL), which is selected from RTL alpha and RTL beta, is inactivated, or are autologous T-cells from the patient diagnosed with cancer; and wherein said cells express a chimeric receptor antigen (CAR) specific to the cancer antigen.

EFFECT: invention provides higher effectiveness of antineoplastic immunotherapy.

18 cl, 27 dwg, 4 ex